ClinicalTrials.gg
CompletedNCT04643457Updated Apr 6, 2026

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

A Phase 1/2 interventional study of UCB9741 and Intravenous Placebo in Atopic Dermatitis, sponsored by UCB Biopharma SRL. Completed at 10 sites in 4 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1/2, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2024, 2 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Dermatitis, Atopic with a site in Bulgaria — 3 open to participants now, 11 under way, 3 of them phase 3. Dermatitis, Atopic · Bulgaria.

Enrollment
38th of 45
107 · median 421
Started
2020
with 3 others
Phase 1/2
Only one
of the 45
Registered
21st of 45
by date

Among the 45 studies in Dermatitis, Atopic with a site in Bulgaria, this one is the 38th largest by enrollment, is one of 4 that started in 2020, is the only one in phase 1/2, and was the 21st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 45 studies in Dermatitis, Atopic with a site in Bulgaria are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Dermatitis, Atopic with a site in Bulgaria, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis. Furthermore, the clinical efficacy outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis
  • Healthy Participants
  • UCB9741
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • Participant must be 18 to 55 years of age inclusive at the time of signing the form (ICF)
  • Participant must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Participant has a (BMI) within the range 18 to 30 kg/m\^2 (inclusive)
  • Participant can be male or female

    • A male participant must agree to use during the Treatment Period and for at least 90 days after the final dose of medicinal product (IMP), and refrain from donating sperm during this period
    • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

      i) Not a woman of (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 90 days after the final dose of IMP

Part B:

  • Participant must be 18 to 65 years of age inclusive at the time of signing the ICF
  • Participant has a documented history of moderate or severe atopic dermatitis (AtD) that has been present for at least 12 months prior to initiating the study (signing of the ICF) and with:

    • validated Investigator Global Assessment (vIGA) score ≥3 at Screening (Visit 1) and Baseline (Visit 2)
    • Eczema Area and Severity Index (EASI) score of ≥14 at Screening (Visit 1) and ≥16 at Baseline (Visit 2)
    • Pruritus Numerical Rating Scale (NRS) score ≥ 3 at Screening (Visit 1) and Baseline (Visit 2)
    • ≥10% body surface area (BSA) of AtD involvement at Screening (Visit 1) and Baseline (Visit 2)
    • Either documented recent history (within 6 months before the Screening Visit) of inadequate response to treatment with topical medications (regular use of topical [TCS] or topical calcineurin inhibitors [TCIs]) or when topical treatments are confirmed to be otherwise medically inadvisable (eg, because of important side effects or safety risks). Inadequate response is defined as failure to achieve and maintain remission or low disease remission or a low disease activity state (validated Investigator Global Assessment (vIGA) 0=clear to vIGA 2=mild) despite treatment with a daily regimen of TCS of medium to higher potency (±TCI as appropriate), applied for at least 4 weeks or for the maximum duration recommended by the product prescribing information (eg, 2 weeks for high potency TCS), whichever is shorter
  • Participant has a body mass index (BMI) within the range 18 to 32 kg/m\^2 (inclusive)
  • Participant can be male or female
  • A male participant must agree to use contraception during the Treatment Period and for at least 60 days after the final dose of IMP, and refrain from donating sperm during this period
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 60 days after the final dose of IMP

Exclusion criteria

Exclusion Criteria:

Part A:

  • Participant has a known to any components of the medicinal product (IMP) or other biologic drugs as stated in this protocol
  • Participant has a significant allergy to humanized monoclonal antibodies (mAbs)
  • Participant has multiple or severe drug allergies, intolerance to topical , or severe posttreatment hypersensitivity reactions
  • Participant has abnormal blood pressure (BP) (outside the normal range) in a supine position after 5 minutes rest
  • Participant has (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >1.0x (ULN)
  • Participant has a recent history or currently active clinically-significant bacterial, fungal, endoparasite, or viral (including hospitalization for coronavirus disease 2019 (COVID-19)) infection (within 6 months of the Screening Visit)
  • Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
  • Participant has a history of diabetes
  • Participant has a interval (QTc) >450 msec
  • Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits), within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than (oral, implants, or intrauterine devices) or occasional use of analgesics, such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4 g/day and 10 g/14 days)
  • Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or within 90 days after the final dose of IMP
  • Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit
  • Participant has participated in another study of an IMP within the previous 90 days or 5 half-lives of the IMP (whichever longer), or is currently participating in another study of an IMP
  • Participant has sensitivity to heparin or heparin-induced thrombocytopenia

Part B:

  • Participant has a known hypersensitivity to any components of the IMP or other biologic drugs as stated in this protocol
  • Participant has significant allergies to humanized mAbs
  • Participant has clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
  • Participant has abnormal BP (outside the normal range) in a supine position after 5 minutes rest
  • Participant has ALT, AST, or ALP >1.5xULN
  • Participant has a recent history of or clinically active clinically-significant, as judged by the Investigator, bacterial, fungal, endoparasite, or viral (or any history of hospitalization for COVID-19) infection (within 6 months of the Screening Visit)
  • Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
  • Participant has a history of diabetes that is not well controlled with diet
  • Participant has a mean QT interval (QTc) >450 msec for male study participants or >470 msec for female study participants
  • Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits) within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implants, or intrauterine devices) or occasional use of analgesics such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4 g/day and 10 g/14 days) or intranasal corticosteroids for seasonal rhinitis or inhaled bronchodilators and low dose inhaled corticosteroids for mild asthma
  • Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or is anticipated to do so within 60 days after the final dose of IMP
  • Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit
  • Participant has participated in another study of an IMP within the previous 30 days or 5 half-lives of IMP (whichever longer) from the Baseline Visit or is currently participating in another study of an IMP
  • Participant has sensitivity to heparin or heparin-induced thrombocytopenia
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Part A: Intravenous UCB9741 arm 1

    Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

    Drug: UCB9741

  • Experimental
    Part A: Intravenous UCB9741 arm 2

    Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

    Drug: UCB9741

  • Experimental
    Part A: Intravenous UCB9741 arm 3

    Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

    Drug: UCB9741

  • Experimental
    Part A: Intravenous UCB9741 arm 4

    Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

    Drug: UCB9741

  • Experimental
    Part A: Intravenous UCB9741 arm 5

    Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

    Drug: UCB9741

  • Experimental
    Part A: Subcutaneous UCB9741 arm 1

    Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.

    Drug: UCB9741

  • Experimental
    Part A: Subcutaneous UCB9741 arm 2

    Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.

    Drug: UCB9741

  • Placebo comparator
    Part A: Intravenous Placebo arm

    Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.

    Drug: Intravenous Placebo

  • Placebo comparator
    Part A: Subcutaneous Placebo arm

    Subjects randomized to this arm will receive subcutaneous Placebo to maintain the blinding.

    Drug: Subcutaneous Placebo

  • Experimental
    Part B: Intravenous UCB9741 arm

    Subjects randomized to this arm will receive pre-specified intravenous doses of UCB9741.

    Drug: UCB9741

  • Placebo comparator
    Part B: Intravenous Placebo arm

    Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.

    Drug: Intravenous Placebo

Interventions

  • \- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

  • DrugIntravenous Placebo

    \- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.

  • DrugSubcutaneous Placebo

    Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.

06

What researchers measure

Primary outcomes

  1. Incidents of treatment-emergent adverse events (TEAEs) during Part A

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline up to the End of Study Visit (Week 12)

  2. Incidents of treatment-emergent serious adverse events (TESAEs) during Part A

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity, or * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline up to the End of Study Visit (Week 12)

  3. Incidents of TEAEs during Part B

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline up to the End of Study Visit (Week 18)

  4. Incidents of TESAEs during Part B

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity, or * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline up to the End of Study Visit (Week 18)

  5. ≥75% improvement vs Baseline in Eczema Area and Severity Index (EASI75) score during Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Cmax from Baseline through the End of Study (EoT) Visit of Part A

    Cmax: Maximum observed serum concentration

    Time frame: From Baseline through the End Of Study Visit (Week 12)

  2. Tmax from Baseline through the End of Study (EoT) Visit of Part A

    tmax: Time to maximum observed serum concentration

    Time frame: From Baseline through the End of Study Visit (Week 12)

  3. AUC(0-t) from Baseline through the End of Study (EoT) Visit of Part A

    AUC(0-t): Area under the serum concentration-time curve from time zero to time t

    Time frame: From Baseline through the End of Study Visit (Week 12)

  4. AUC from Baseline through the End of Study (EoT) Visit of Part A

    AUC: Area under the serum concentration-time curve from time 0 to last observed quantifiable concentration

    Time frame: From Baseline through the End of Study Visit (Week 12)

  5. F% from Baseline through the End of Study (EoT) Visit of Part A

    F%= Bioavailability of subcutaneous route

    Time frame: From Baseline through the End of Study Visit (Week 12)

  6. Percent change from Baseline in the Eczema Area and Severity Index (EASI) score at Week 12 of Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: Baseline, Week 12

  7. ≥50% improvement vs Baseline in EASI score (EASI50) at Week 12 during Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: Baseline, Week 12

  8. ≥90% improvement vs Baseline in EASI score (EASI90) at Week 12 during Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: Baseline, Week 12

  9. Cmax after the final dose of Part B

    Cmax: Maximum observed serum concentration

    Time frame: Week 12

  10. Tmax after the final dose of Part B

    tmax: Time to maximum observed serum concentration

    Time frame: Week 12

  11. AUCtau at Week 12 of Part B

    AUCtau: Area under the curve for the dosing interval after the final dose

    Time frame: Week 12

07

Study locations

10 sites
  • Up0089 303
    Pleven, Bulgaria
  • Up0089 301
    Sofia, Bulgaria
  • Up0089 304
    Sofia, Bulgaria
  • Up0089 407
    Berlin, Germany
  • Up0089 408
    Heidelberg, Germany
  • Up0089 410
    Leipzig, Germany
  • Up0089 201
    Leiden, Netherlands
  • Up0089 104
    Liverpool, United Kingdom
  • Up0089 101
    London, United Kingdom
  • Up0089 103
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2024, 40 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 40 months is above that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2020
First posted
Nov 25, 2020
StartActual
Nov 27, 2020
Primary completionActual
Apr 23, 2024
CompletionActual
Jun 6, 2024
Results delay requested
Apr 22, 2025
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04643457
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Nov 27, 2020
Primary completion
Apr 23, 2024
Completion
Jun 6, 2024
Last update
Apr 6, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Galvokimig

Start the discussion